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Abstract 
Several members of a family died with renal failure due to systemic amyloidosis.  Extensive 
studies to detect previously documented gene mutations associated with amyloidosis failed to 
identify a causative factor.  In search for the genetic basis for this syndrome amyloid fibrils were 
isolated from renal tissue of a member of the kindred who died while on renal dialysis.  Amino 
acid sequencing of isolated amyloid protein identified sequences compatible with the constant 
region of the immunoglobulin kappa light-chain.  Isolation and characterization of kappa light-
chain protein from serum of an affected member of the kindred revealed mutation in the constant 
region of kappa light-chain with cysteine replacing serine at amino acid residue 131.  This 
mutation (Ser131Cys) was confirmed by DNA analysis which identified a single base change of 
cytosine to guanine at the second position of codon 131 of the kappa light-chain gene 
(TCT131TGT).  DNA analysis of members of the extended family revealed transmission of the 
Ser131Cys mutation and association with systemic amyloidosis.  This form of AL amyloidosis 
which is a hereditary type of amyloidosis and not the result of a monoclonal plasma cell 
dyscrasia may be misdiagnosed and lead to inappropriate chemotherapy. 
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Introduction 
Immunoglobulin light-chain amyloidosis (AL) is the most frequent form of systemic 
amyloidosis.1  It is a sporadic disease due to plasma cell dyscrasia with resulting amyloid fibril 
formation from monoclonal immunoglobulin light-chain either kappa or lambda.  There are, 
however, a number of forms of systemic amyloidosis which are caused by mutations in other 
plasma proteins and are expressed with autosomal dominant genetics.2 These inherited forms of 
amyloidosis may show predilection for specific organ involvement such as the heart, peripheral 
nervous system, or kidney, but are all systemic in nature and very often clinically mimic AL 
amyloidosis.  A number of the inherited forms of systemic amyloidosis cause renal 
manifestations and, therefore, may be mistaken for AL amyloidosis which often presents with 
major renal dysfunction.3    
While plasma cell dyscrasia may be more prevalent in certain families, AL amyloidosis 
has rarely been reported in first degree relatives and no definite inheritance pattern has been 
identified.  Here we report a systemic form of immunoglobulin light-chain amyloidosis which is 
inherited as an autosomal dominant trait and is associated with a mutation in the constant region 
of the kappa immunoglobulin light-chain. 
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Methods  
The family 
Six members (4 men and 2 women) of a family of eight died with renal failure between 53 and 
74 years of age (Figure 1).  Five had received renal dialysis.  Four (II-3, II-8, II-10, II-12) had the 
diagnosis of amyloidosis made by renal biopsy.  Their mother (I-2) had died at age 58 with renal 
failure.  
In the next generation, one man (III-2) with biopsy proven renal amyloidosis died at age 
74 after several years treatment with renal dialysis, and two cousins (III-12 and III-15) have 
biopsy proven amyloidosis, one on renal biopsy (III-12) and one on gastric mucosal biopsy (III-
15, index case). 
Review of medical histories revealed that one man (II-3) who died of renal failure also 
had amyloid deposition on laryngeal and lung biopsies verifying that he had a systemic form of 
amyloidosis.  Medical records indicated that immunohistological analysis of kidney biopsies for 
four individuals showed positive staining for kappa light-chain, and laser dissected mass 
spectrometry analysis of amyloid identified on a gastric biopsy of a member of the third 
generation (III-15) identified kappa light-chain constant region peptides. 
Amyloid protein characterization 
Amyloid fibrils were isolated from formalin-fixed, paraffin-embedded renal tissue of one 
member of the family who died while on dialysis.4  Tissue was solubilized in 8 M guanidine-HCl 
under reducing conditions, and solubilized protein subjected to amino acid sequencing on an 
Applied Biosystems Procise 491 cLC protein sequencer using the manufacturer’s standard cycles 
5 
and methods.  Isolated protein was also subjected to tryptic digestion and resultant peptides 
separated by reverse phase HPLC and characterized by amino acid sequencing.5 
Immunoglobulin light-chain isolation and characterization 
Serum (10 ml) from a member of the kindred with biopsy proven amyloidosis was made 33% 
saturated with ammonium sulfate at room temperature.  The precipitated fraction recovered by 
centrifugation was dissolved in PBS and chromatographed on a Sepharose CL6B column 
equilibrated and eluted with PBS.  The major peak, which on SDS-PAGE analysis in the 
presence of 2-mercaptoethanol contained 25 kDa and 50 kDa bands (immunoglobulin light-chain 
and heavy-chain), was dialyzed against distilled water and lyophilized.  Dried protein was 
solubilized in 8 M guanidine hydrochloride, 0.5 M Tris pH 8.2 containing 10 mg 
dithiothreitol/ml, alkylated with iodoacetic acid, and centrifuged.  Chromatography of the 
supernatant on Sepharose CL6B equilibrated and eluted with 4 M guanidine hydrochloride, 25 
mM Tris pH 8.2 yielded two major peaks corresponding to Ig heavy and Ig light-chains.  
Fractions containing Ig light-chains were combined, exhaustively dialyzed against distilled water 
and lyophilized.  After tryptic digestion, peptides were separated by HPLC on a Beckman 
Ultrasphere ODS column and isolated peptides subjected to amino acid sequencing on an 
Applied Biosystems Procise 491 cLC protein sequencer using the manufacturer’s standard cycles 
and methods. 
Histochemistry 
Tissue biopsy sections (4 micron) were stained with haematoxylin and eosin.  Sections were also 
stained with alkaline Congo red.  Immunohistochemistry of biopsy tissues was performed by the 
indirect immunoperoxidase technique using rabbit anti-kappa and anti-lambda polyclonal 
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antisera and immunoperoxidase labeled goat anti-rabbit IgG antibody.  Sections were developed 
with diaminobenzidine.  
DNA analysis 
DNA was isolated from EDTA-treated blood and formalin-fixed, paraffin-embedded tissue.6  
PCR amplification of the constant region of the kappa light-chain gene used primers 5’ 
ACCATCCTGTTTGCTTCT 3’ and 5’CTCTGTGACACTCTCCTG 3’ with standard cycles 1 
min 94°, 1 min 56°, 1 min 72° for 35 cycles.  Sequencing was performed by a Beckman CEQ 
System. 
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Results 
Review of medical records for several members of a family who died with renal failure 
documented that kidney biopsies demonstrated amyloid deposition in glomerular basement 
membrane and blood vessel walls.  In several cases positive staining for kappa light-chain was 
described but evaluation for monoclonal gammopathy was negative (Table 1).  In the present 
study amyloid deposition in a renal biopsy of subject III-12 was identified by routine histology, 
and electron microscopy demonstrated 7-10 micron fibrils consistent with amyloid (Figure 2).  
Immunohistochemistry for kappa light-chain performed on cholecystectomy tissue from the 
index case (III-15) gave positive staining of blood vessel walls which coincided with Congo red 
staining (Figure 3).7     
Amino acid sequence analysis of tryptic peptides of amyloid fibril protein isolated from 
post-mortem formalin-fixed paraffin-embedded kidney tissue gave sequences consistent with 
immunoglobulin kappa light-chain constant region, residues 109-120, 127-142, 150-163, 170-
179, and 191-205 (Figure 4).  All numbering is according to the Kabat numbering system.8  
Residue 131 which is normally a serine and residue 134 which is normally cysteine could not be 
positively identified.   
Immunoglobulin light-chain proteins were isolated from serum of an affected family 
member and subjected to amino acid sequencing which identified the entire kappa constant 
region except for amino acid residues 143-145, 172-183, and 208-214 (Figure 4).  Of note was 
identification of separate peptides containing either serine or cysteine at position 131.  Position 
134 had only the normal cysteine which is involved in the intramolecular disulfide bridge to the 
cysteine at position 194. 
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Nucleotide sequencing of the constant region of the kappa light-chain gene in the subject 
described above (III-15) whose kappa light-chain serum protein had both serine and cysteine at 
position 131 showed guanine as well as the normal cytosine in the second position of codon 131 
(nucleotide 403).  The cytosine to guanine transversion gives a sequence encoding cysteine 
(TGT) in place of serine (TCT) consistent with the presence of cysteine 131 in the kappa light-
chain protein (Figure 5). 
Sequencing of DNA isolated from post mortem tissue of the subject whose amyloid fibril 
protein had been characterized also showed heterozygosity for the Ser131Cys change in the 
kappa light-chain gene.  In addition, two children of subject II-7 who died with amyloidosis were 
positive for the Ser131Cys mutation indicating that their affected parent (II-7) had been an 
obligate carrier of the Ser131Cys mutation.   
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Discussion 
All forms of hereditary systemic amyloidosis identified so far are inherited in an autosomal 
dominant pattern which is consistent with the structural nature of mutant proteins that form 
amyloid fibrils.2  Mutation in only one allele is sufficient for production of protein that can 
follow the amyloid fibril forming pathway. 
In the usual type of Ig light-chain amyloidosis (AL) no hereditary pattern has been 
identified and the disease is considered “sporadic”.  The only definite requirement for amyloid 
formation appears to be a plasma cell dyscrasia that produces excess monoclonal amyloid fibril 
precursor protein.  In addition, it has been proposed that certain amino acid residues in the 
variable region of the light-chain predispose to fibril formation with certain light-chain structures 
(e.g. lambda-6) having more fibril forming potential.9,10  While structure of the variable region 
dictates fibril formation, it is common to find some portions of the light-chain constant region, 
either kappa or lambda, in the final fibril product. 
The immunoglobulin kappa light-chain amyloidosis described here is different.  The 
disease is obviously hereditary and segregates with a Ser131Cys mutation in the constant region 
of the kappa light-chain gene.  No significant amount of peptide sequence consistent with any 
known kappa variable region was identified in isolated fibrils.  In one case subjected to mass 
spectrometry analysis, minor amounts of kappa variable peptide sequences were noted but 
included kappa–I, –II, and –III, and would not support presence of a monoclonal 
immunoglobulin (Figure 6).  
Essentially these are two different diseases, one the result of a monoclonal plasma cell 
dyscrasia in which the specific variable region of the light-chain is predisposed to amyloid fibril 
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formation when produced in excess.  The other is the result of a mutation in the light–chain 
constant region gene which, for an individual heterozygous for the mutation, predictably would 
be present in 50% of serum IgG kappa antibodies.  Excess production of the mutated constant 
region peptide is not likely to be a determining factor in amyloid formation, although stimulation 
of antibody production by repeated immunizations or response to infectious diseases could 
possibly be a factor in initiation and progression of amyloid formation.  More likely age-related 
metabolic factors in the catabolism of serum proteins, as with other forms of hereditary 
amyloidosis, dictate the late-onset of amyloid formation from a protein that has been present 
from birth.  Review of the published tertiary structure of the kappa light-chain constant region 
obtained by X-ray diffraction indicates that the cysteine at position 131 may cause marked 
change in protein folding but it is not likely to interfere with the normal intramolecular disulfide 
bridge from 134Cys to 194Cys (Figure 7).11 
There are two reports of cases in which mutation in the kappa constant gene was 
associated with systemic amyloidosis.12,13  Both had a kappa light-chain mutation (Ser177Asn) 
identified in amyloid fibril isolates and both were from patients with plasma cell dyscrasias.  In 
the case reported by Solomon, et al.,12 nucleotide sequencing of DNA from family members of 
the patient with light-chain amyloidosis was consistent with the Ser177Asn kappa constant 
region change being the result of a germ-line rather than a somatic mutation.  A similar 
conclusion was proposed by the studies of Wally, et al.,13 with the suggestion that the Ser177Asn 
did not cause but contributed to the generation of amyloid formation.  In both of the reported 
cases12,13 rapid progression of clinical disease was noted.  While it has been proposed that 
Ser177Asn is a kappa light-chain polymorphism as are Ala153Val and Val191Leu, additional 
studies are needed to support this hypothesis.  Since there are no reports identifying the kappa 
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light-chain constant region Ser131Cys mutation in published studies, it is unlikely to meet the 
designation of a genetic polymorphism. 
There have also been reports of AL amyloidosis in first degree relatives.  Miliani, et al., 
reported three siblings with AL amyloidosis.14  Gertz, et al., reported AL amyloidosis in three 
families.15  Enquist, et al., reported a father and son with AL amyloidosis.16  In all of these cases 
an underlying plasma cell dyscrasia was identified.  Extensive searches for plasma cell dyscrasia 
in several of the patients in the present report of kappa light-chain amyloidosis were negative. 
This is the first report of AL amyloidosis due to an identified mutation in the constant 
region of an immunoglobulin light-chain gene in the absence of a monoclonal plasma cell 
dyscrasia.  In the present family the high incidence of affected individuals makes the hereditary 
nature of the disease obvious and this probably has protected them from inappropriate treatment 
with chemotherapy designed to treat plasma cell dyscrasia.  One can only speculate as to whether 
other mutations in the constant region of light-chain genes, kappa or lambda, might give 
systemic amyloidosis without the presence of a plasma cell dyscrasia.  If no obvious family 
history of amyloidosis is present, a misdiagnosis and inappropriate treatment with chemotherapy 
might result.  It is also possible that amyloidosis could result from a somatic mutation in the 
constant region of the light-chain gene.  In such a case there would be no family history of 
amyloidosis.  In the small, but significant, number of patients with AL amyloidosis who do not 
have a detectible plasma cell dyscrasia by present testing methods nucleotide sequencing of the 
Ig light-chain constant region genes should be considered as part of the diagnostic evaluation. 
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Table 1.  Clinical features of C kappa amyloidosis. 
SUBJECT CLINICAL FEATURES 
AGE AT 
DEATH 
TISSUE-POSITIVE 
AMYLOID 
BONE 
MARROW 
IMMUNOGLOBULIN 
LIGHT-CHAIN 
Kappa131Cys 
I-2 Renal Failure 58 
II-1 Renal Failure – age 52 53 
II-3 
Renal Failure – age 60 
Dialysis – age 64 
66 
Kidney, Larynx, Lung, 
Bone marrow 
Hypocellular 
II-7 
Renal Failure 
Dialysis 
73 
II-8 
Renal Failure 
Dialysis 
54 Kidney 
II-10 
Renal Failure 
Dialysis 62 
Post-mortem Kidney, 
Heart, Pancreas, 
Parathyroid 
Hypocellular 
+ 
II-12 
Renal Failure – age 60+ 
Dialysis 
III-2 
Renal Failure – age 66 
Dialysis – age 70 
74 Kidney 
III-8 Alive – 73 years –
III-9 
Proteinuria – age 64 
(Stage 3 renal disease) 
Increased kappa 
and lambda 
+ 
III-10 Asymptomatic – age 37 + 
III-12 Proteinuria – age 66 Kidney Normal + 
III-15 Cholecystitis – age 53 Stomach, 
Gall bladder 
Normal Normal + 
IV-1 –
IV-2 –
IV-3 
IV-4 Asymptomatic – age 40 Normal + 
IV-5 Asymptomatic – age 39 Normal + 
IV-6 –
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Figure Legends 
1. Pedigree of family showing members with biopsy proven amyloidosis ( ) and presumed
affected (◩) showed typical autosomal dominant inheritance.  The index case is indicated by 
arrow.   
2. Kidney biopsy from subject III-12:  (A) Haematoxylin and eosin stained section showing
deposits in glomerular basement membrane (original X 100).  (B) Electron micrograph showing 
amyloid deposits with 7-10 nm fibrils (insert) consistent with amyloid. 
3. Serial microscopic sections of gallbladder wall from index patient (III-15):  (A) Stained with
Congo red and viewed by fluorescence microscopy.  (B) Stained by indirect 
immunohistochemistry with polyclonal anti-Ig kappa light-chain antiserum showing specific 
staining of amyloid deposits (original X 100). 
4. Amino acid sequences of tryptic peptides of (A) amyloid fibril protein isolated from post-
mortem kidney of patient II-10, and (B) plasma kappa light-chain from a member of the next 
generation (III-15) with biopsy proven amyloidosis.  The normal sequence of the constant region 
of kappa light-chains is shown.  Residue numbering is by Kabat et al.8   The lines indicate the 
sequences obtained by Edman degradation of HPLC purified tryptic peptides.  The parentheses at 
the ends of the amyloid fibril protein peptides (A) denote residues not completely verified due to 
decreasingly low Edman degradation yields.  The X at residues 131 and 134 denote no amino 
acid was identified at these positions.  The dots at the ends of some plasma light-chain peptides 
(B) indicate that the peptide continued but was not analyzed further. 
5. Nucleotide sequence of PCR product for kappa light-chain DNA showing heterozygosity at
cDNA position 403 with both cytosine and guanine giving coding sequence for cysteine (TGT) 
and serine (TCT) at position 131. 
6. Report of LCMS analysis of gastrointestinal biopsy amyloid from index case (III-15).
7. Ribbon diagram of kappa light-chain molecular structure to show position of the Ser131
residue in relation to the Cys134 which is part of the normal intramolecular disulfide bridge. 
Modified from A. Roussel, et al., Eur J Biochem 1999;260(1):192-199.11
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